Found 17 Liver Disease trials
A listing of Liver Disease medical research trials actively recruiting patient volunteers. Search for closest city to find more detailed information on a research study in your area.
The main purpose of this study is to determine if certain genes, hormones, or other factors predict the risk of developing lung vessel disease in patients with liver disease and whether they determine outcome. Patients in need of a liver transplant evaluation or have portopulmonary hypertension or are suspected of …
You are invited to participate in a research study that will look at the impact of primary sclerosing cholangitis on the gut.
The purpose of the HepQuant SHUNT study is to validate the Disease Severity Index (DSI) from the HepQuant SHUNT Test for likelihood of large esophageal varices by comparing the SHUNT test to the current standard of care, EGD, in patients with chronic liver disease.
A phase 2B, randomized, double-blind, placebo-controlled study evaluating the safety and efficacy of BMS-986036 in subjects with NASH and F3 fibrosis. The treatment period is 48 weeks, with drug administered as a once-weekly injection. There is also a follow-up period to assess long-term bone mineral density and immunogenicity. Target population …
In this study, the Investigator at the University of Pennsylvania will assess organ-specific biomarker profiles (proteins and metabolites), in order to better understand biologic processes, the interplay between the heart and extracardiac organs, and their role in human disease, with an emphasis on cardiovascular disease. The study will specifically focus …
Indocyanine Green (ICG) is an FDA approved, water-soluble tricarbocyanine dye routinely used in clinical settings for measuring cardiac output, liver function, and retinal angiography and has been in use for over 50 years. Patient diagnosed with solid tumor cancers have a high rate of recurrence when surgery is a treatment. …
A phase 2B, randomized, double-blind, placebo-controlled study evaluating the safety and efficacy of BMS-986036 in subjects with NASH and compensated cirrhosis. The treatment period is 48 weeks, with drug administered as a once-weekly injection. There is also a follow-up period to assess long-term bone mineral density and immunogenicity. Target population …
You are being asked to be in this research study because you have PBC (primary biliary cholangitis) which is an uncommon chronic cholestatic liver disease characterized by progressive inflammation and destruction of the interlobular bile ducts, ultimately leading to the development of biliary cirrhosis.
1 - 10 of 17
- 1
- 2
